HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.05.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Christian Ammitzbøll Juul und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Liposomes, Erb-b2 Receptor Tyrosine Kinases, Oxaliplatin. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Lundbeck Foundation, European Research Council.
Abstract (Originalsprache)
Liposomes carrying chemotherapeutic drugs can accumulate passively in solid tumors at high levels. However, additional targeting of the liposomes towards e.g. receptors expressed on cancer cells may improve their interaction and therapeutic properties. In this study, we designed a liposomal delivery system, which utilizes the intrinsic characteristics of HER2-positive tumors to ensure efficient delivery of oxaliplatin to the cancer cells. On the liposome surface, trastuzumab, an antibody specific to the HER2 receptor, was shown to facilitate internalization by the cancer cells. A polyethylene glycol (PEG) layer on the liposome surface provides protection from mononuclear phagocyte system uptake. To optimize the interaction between liposomes and cancer cells, a protease-sensitive cleavable peptide linker was inserted at the base of each PEG. The PEG layer is then cleaved off by intra- and extracellular matrix metalloproteinases (MMPs) upon accumulation in the tumor. Our data demonstrate that the removal of PEG significantly destabilizes the liposomes and leads to substantial oxaliplatin release. The proposed beneficial effect of combining antibody-mediated internalization with MMP sensitivity was confirmed in a series of in vivo studies using ovarian cancer xenograft models. The results demonstrated that HER2-targeted MMP-sensitive liposomes have superior anticancer activity compared to non-targeted and non-cleavable liposomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
- Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, 2100 Copenhagen Ø, Denmark; d, Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical…
- DTU Nutech, Center for Nuclear Technologies, Technical University of Denmark, 4000 Roskilde, Denmark.
- Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. Electronic address: tlan@dtu.dk.
Förderung
- Lundbeck Foundation
- European Research Council
Zitieren
APA
Juul, C. A., Engel, T. B., Fliedner, F. P., Ringgaard, L., Eliasen, R., Melander, F., Bak, M., Kjær, A., Henriksen, J. R., Elema, D. R., Hansen, A. E., & Andresen, T. L. (2024). HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.05.005
Vancouver
Juul CA, Engel TB, Fliedner FP, Ringgaard L, Eliasen R, Melander F, et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.05.005
BibTeX
@article{Juul2024,
author = {Juul, Christian Ammitzbøll and Engel, Trine Bjørnbo and Fliedner, Frederikke Petrine and Ringgaard, Lars and Eliasen, Rasmus and Melander, Fredrik and Bak, Martin and Kjær, Andreas and Henriksen, Jonas Rosager and Elema, Dennis Ringkjøbing and Hansen, Anders Elias and Andresen, Thomas Lars},
title = {HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.05.005}
}
EUVIMED